Hal Barron

Effective August 1, 2022, Dr. Barron will join Altos Labs as CEO and Board Co-Chair. He is currently Chief Scientific Officer and President, R&D at GSK, where he is responsible for all research and development activities across the globe including life-cycle management for all marketed products. Dr. Barron is a member of the GSK Board of Directors as an executive director and will transition to the non-executive director on August 1.

Prior to joining GSK, Dr. Barron was President, R&D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to this role, he was Executive Vice President, Head of Global Product Development, and Chier Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, Dr. Barron was Senior Vice President of Development and Chief Medical Officer. He was a non-executive director and chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. He also previously served as a non-executive Board Director of GRAIL, Inc until it was acquired by lumina. He was also an Advisory Board Member of Verily Life Sciences LLC until 2021.